Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amarillo Biosciences, Inc.
Oral interferon provided for M.D. Anderson clinical trial in patients with bone marrow disorders
October 26th, 2005
Amarillo Biosciences, Inc., (ABI, AMAR) announced that a study to test low dose oral interferon alpha in 40 patients with rare bone marrow proliferative disorders is now open to enrollment. Amarillo Biosciences filed the Investigational New Drug Application with the U.S. Food and Drug Administration (FDA), and, in conjunction with principal investigator Srdan Verstovsek, MD, PhD, assistant professor, Myeloproliferative Disorders Program Leader, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, helped to develop the protocol for the clinical trial. In addition, Amarillo Biosciences will provide the low dose oral interferon that will be used in the...
Source: Elder Law Weekly (2005-10-26)
|
